<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103060</url>
  </required_header>
  <id_info>
    <org_study_id>DMVT-502-2101</org_study_id>
    <nct_id>NCT04103060</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermavant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermavant Sciences GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety,&#xD;
      tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Actual">November 3, 2020</completion_date>
  <primary_completion_date type="Actual">November 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Baseline through Week 7</time_frame>
    <description>Body temperature, blood pressure, pulse (heart rate), and breathing rate (respiratory rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>Baseline through Week 7</time_frame>
    <description>Clinically significant abnormal lab values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline through Week 7</time_frame>
    <description>Frequency, severity, and duration of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Tolerability Scale Score</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6, and Week 7</time_frame>
    <description>Assessment of local site investigational product administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of cerdulatinib</measure>
    <time_frame>Days 1, 15, 29 and 43</time_frame>
    <description>Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blister fluid biomarker concentration</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>From active treated lesions and untreated nonlesional skin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Cerdulatinib 0.37% gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerdulatinib 0.37% gel applied topically twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel applied topically twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerdulatinib 0.37% gel</intervention_name>
    <description>Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks</description>
    <arm_group_label>Cerdulatinib 0.37% gel</arm_group_label>
    <other_name>DMVT-502</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>Vehicle gel applied topically twice daily for 6 weeks</description>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects age 18 and older with a confirmed clinical diagnosis of&#xD;
             vitiligo for at least 3 months, including ≥0.5% to ≤30% BSA involvement.&#xD;
&#xD;
          -  Females of child bearing potential and male subjects who are engaging in sexual&#xD;
             activity that could lead to pregnancy agree to follow the specified contraceptive&#xD;
             guidance throughout the study&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of segmental vitiligo&#xD;
&#xD;
          -  Subjects with concurrent conditions or history of other diseases (e.g., current or&#xD;
             chronic history of liver disease) that could affect the safety of the subject or the&#xD;
             implementation of this study&#xD;
&#xD;
          -  Use of any prohibited medication within the indicated period before the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources&#xD;
             of UV radiation within 8 weeks prior to the Baseline visit and/or plans to have such&#xD;
             exposures during the study which could potentially impact the subject's vitiligo&#xD;
&#xD;
          -  The subject has received an investigational product within the following time period&#xD;
             prior to the first dosing day: 4 weeks or 5 half-lives (whichever is longer).&#xD;
&#xD;
          -  Evidence of significant hepatic, renal, respiratory, endocrine, hematologic,&#xD;
             neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory&#xD;
             test value abnormality that will affect the health of the subject or interfere with&#xD;
             interpretation of the results&#xD;
&#xD;
          -  History of sensitivity to the study drug, or components thereof or a history of drug&#xD;
             or other allergy that contraindicates the subject's participation in the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McLaughlin</last_name>
    <role>Study Director</role>
    <affiliation>Dermavant Sciences GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermavant Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

